Overview

Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, double-blind, crossover pilot study to measure the safety and feasibility of Interleukin-1 (IL-1) blockade with Anakinra in patients with stable heart failure with preserved ejection fraction.
Phase:
N/A
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
American Heart Association
Treatments:
Interleukin 1 Receptor Antagonist Protein